MedTrace Logo

Investigation of the Pharmacokinetic Profile of CBD - Phase 1 ANANDA

NCT05023070 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-09-29

No results posted yet for this study

Summary

The goal of the current study is to evaluate the bioavailability of CBD in normal healthy Individuals. This is an open cross-over design study in healthy individuals to assess the safety and pharmacokinetic (PK) effects of cannabidiol.

Conditions

  • Healthy

Interventions

DRUG

Cannabidiol

Cannabidiol 200 mg

DRUG

Cannabidiol

Cannabidiol 400 mg

DRUG

Cannabidiol

Epidiolex 400 mg

DRUG

Cannabidiol

Cannabidiol 400 mg

Sponsors & Collaborators

Principal Investigators

  • Yasmin Hurd · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-22
Primary Completion
2023-02-16
Completion
2023-02-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05023070 on ClinicalTrials.gov